Overview

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Status:
Completed

Trial end date:
2018-02-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the mycobactericidal activity of combinations of bedaquiline (J), moxifloxacin (M), PA-824 (Pa) and pyrazinamide (Z) regimens during 8 weeks of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Global Alliance for TB Drug Development

Treatments:

Bedaquiline
Diarylquinolines
Ethambutol
Fluoroquinolones
Isoniazid
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Pyrazinamide
Rifampin